Clearmind Medicine Inc.CMND
Key ratios
ROA
-53.1%2025
2024
-54.4%2023
-116.2%
ROE
-179.4%2025
2024
-256.9%
Recent news
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial
Clearmind Advances MDMA-N-acylethanolamines IP for Treatment of PTSD
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation Supporting Enhanced Nasal Retention Without Compromising Drug Delivery
Track CMND in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer